Carlyn Tan

Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

IF11.6

2026-09-220

OAAI

Noriko Nishimura; Samantha Brown; Sarah Samorodnitsky; Sean M. Devlin; Mohammad Alhomoud; Parastoo Dahi; Charlotte Hughes; Eric Jergens; Heather J. Landau; Oscar B. Lahoud; Michael Scordo; Gunjan L. Shah; Ross Firestone; Hamza Hashmi; Hani Hassoun; Malin Hultcrantz; Neha Korde; Alexander M. Lesokhin; Kylee Maclachlan; Sham Mailankody; Francesco Maura; Maximilian Merz; Sridevi Rajeeve; Urvi A. Shah; Carlyn R. Tan; Gaurav K. Gupta; Elena Maryamchik; Evangelos Ntrivalas; Qi Gao; Mikhail Roshal; Saad Z. Usmani; Sergio A. Giralt; David J. Chung

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响：在复发/难治性多发性骨髓瘤中的作用

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

IF11.6

2026-08-070

OAAI

在多发性骨髓瘤患者中，强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关（cilta-cel治疗）

Science Translational Medicine

IF14.6

2026-07-290

PRE

Eric M. Jurgens; Sneha Mitra; Kevin Herrera; David Nemirovsky; Brenden Bready; Andriy Derkach; Kinga Hosszu; Devin McAvoy; Ross S. Firestone; Sridevi Rajeeve; Alexander M. Lesokhin; Neha Korde; Carlyn R. Tan; Hamza Hashmi; Hani Hassoun; Kylee Maclachlan; Urvi A. Shah; Malin Hultcrantz; Maximilian Merz; Francesco Maura; Sergio A. Giralt; Gunjan L. Shah; Heather J. Landau; Michael Scordo; Ivan S. Kotchetkov; Bianca D. Santomasso; Jae Park; Christina S. Leslie; Saad Z. Usmani; Karlo Perica; Sham Mailankody

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

真实世界中塔尔奎他马单抗治疗复发/难治性多发性骨髓瘤(RRMM)的疗效评估：国际骨髓瘤工作组免疫治疗登记研究的真实世界分析

American Journal of Hematology

IF9.9

2026-05-190

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

Early Mortality with Bispecific Antibody Therapy in RRMM: An IMWG Immunotherapy Database Real-World Analysis

IF11.6

2026-04-120

OAAI

双特异性抗体疗法在RRMM中的早期死亡率：IMWG免疫疗法数据库真实世界分析

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM

IF7.1

2026-02-260

OAAI

IMS-IMWG 2025年共识基因组分期可预测达雷木单抗为基础的四联方案对NDMM的疗效。

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

IF7.1

2026-02-190

OAAI

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

IF11.6

2025-11-010

OAAI

更正：达鲁珠单抗耐药性对复发难治性多发性骨髓瘤接受CAR T细胞治疗后临床结局的影响

Treatment-emergent peripheral neuropathy associated with bortezomib-based frontline regimens for multiple myeloma

IF11.6

2025-10-130

硼替佐米为基础的初治多发性骨髓瘤方案相关治疗相关周围神经病变

LEUKEMIA & LYMPHOMA

IF2.2

2025-10-010

PRE

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

daratumumab难治性对复发性难治性多发性骨髓瘤CAR T细胞治疗后临床结局的影响

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

IF11.6

2025-08-140

OAAI

老年体弱患者接受BCMA靶向双特异性抗体治疗复发/难治性多发性骨髓瘤的结局

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

IF7.1

2025-05-060

在长期剂量延迟后重新开始teclistamab和talquetamab治疗，可能不需要重新进行剂量递增。

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

IF7.1

2025-03-100

商业化CAR T细胞疗法和双特异性抗体治疗复发/难治性多发性骨髓瘤期间的感染并发症

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

IF23.1

2024-11-050

PRE

Jurgens, Eric M.; Shekarkhand, Tala; Farzana, Tasmin; Rueda, Colin; Nemirovsky, David; Derkach, Andriy; Firestone, Ross S.; Nishimura, Noriko; Miller, Kevin; Costa, Bruno Almeida; Nath, Karthik; Rajeeve, Sridevi; Lesokhin, Alexander M.; Korde, Neha; Tan, Carlyn Rose; Hashmi, Hamza; Hassoun, Hani; Maclachlan, Kylee H.; Shah, Urvi A.; Hultcrantz, Malin; Hamadeh, Issam S.; Giralt, Sergio A.; Chung, David J.; Landau, Heather J.; Scordo, Michael; Shah, Gunjan L.; Usmani, Saad Z.; Mailankody, Sham; Shahid, Zainab

自体或异基因造血干细胞移植后，生产抗BCMA CAR T细胞是可行的。

Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

IF23.1

2024-11-050

PRE

定义与Talquetamab逐步增加剂量相关的细胞因子释放综合征的发生率

Body Mass Index Trajectory during Triplet Induction Therapy: Clinical Implications in Newly Diagnosed Multiple Myeloma

IF23.1

2024-11-050

PRE

三联诱导治疗期间体质量指数变化轨迹：新诊断多发性骨髓瘤的临床意义

Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease

IF23.1

2024-11-050

PRE

基因组复杂性与人髓外疾病背景下恶性浆细胞的骨髓独立性程度相关。

Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

IF23.1

2024-11-051

PRE

Maclachlan, Kylee H.; Garces, Juan-Jose; Shekarkhand, Tala; Rajeeve, Sridevi; Hashmi, Hamza; Hassoun, Hani; Hultcrantz, Malin; Korde, Neha; Tan, Carlyn Rose; Mailankody, Sham; Simhal, Anish; Chung, David J.; Shah, Gunjan L.; Scordo, Michael; Giralt, Sergio; Poos, Alexandra Maria; John, Lukas; Zhang, Yanming; Cimera, Robert; Arcila, Maria E.; Ossa, Juan E. Arango; Bhanot, Umesh; Jain, Mala; Merghoub, Tala; Landau, Heather J.; Lesokhin, Alexander M.; Usmani, Saad Z.; Weinhold, Niels; Maura, Francesco; Shah, Urvi A.

老年虚弱及双特异性T细胞接合剂疗法在复发/难治性多发性骨髓瘤患者中的结局